Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 4, 2011, Pages 228-233

  Mafficini, Andrea ^a   Ortombina, Myriam ^b   Sermet Gaudelius, Isabelle ^c   Lebecque, Patrick ^d   Leal, Teresinha ^d   Iansa, Patrizia ^b   Reychler, Gregory ^d   Dahan, Karin ^d   Pepermans, Xaviers ^d   Lenoir, Gerard ^c   Leonard, Anissa ^d   Sorio, Claudio ^a   Assael, Baroukh ^b   Melotti, Paola ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

ABCC1; Cystic fibrosis; Infection by Pseudomonas aeruginosa; Modifier gene; Multidrug Resistance associated Protein 1; NT_010393.16:g.15983174C>G polymorphism; Severity of cystic fibrosis disease

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRESCHOOL CHILD; PROMOTER REGION; PSEUDOMONAS INFECTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CELL LINE; CYSTIC FIBROSIS; DATABASES, FACTUAL; EPITHELIAL CELLS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79958274672     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.10.007     Document Type: Article

References (31)

1. Lester L.A., Kraut J., Lloyd-Still J., Karrison T., Mott C., Billstrand C., et al. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics 1994, 93:114-118.
2. Grasemann H. Disease modifier genes in cystic fibrosis. Eur Respir Mon 2006, 35:50-56. Printed in UK. Copyright ERS Journals Ltd 2006.
3. Abraham E.H., Shrivastav B., Salikhova A.Y., Sterling K.M., Johnston N., Guidotti G., et al. Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis. Blood Cells Mol Dis 2001, 27:165-180.
4. Altschuler E.L. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998, 351:1286.
5. Pradal U., Delmarco A. Long term azithromycin in cystic fibrosis: another possible mechanism of action?. J Chemother 2005, 17:384-400.
6. Cigana C., Nicolis E., Pasetto M., Assael B.M., Melotti P. Effects of the macrolide azithromycin on the expression of ATP-Binding cassette transporters in cystic fibrosis airway epithelial cells. J Chemother 2007, 19:643-649.
7. Lallemand J.Y., Stoven V., Anneraud J.P., et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?. Lancet 1997, 350:711-712.
8. Leslie E.M., Deeley R.G., Cole S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167:3-23.
9. Hurbain I., Sermet-Gaudelus I., Valle B., et al. Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the δF508 mutation. Pediatr Res 2003, 54:627-634.
10. Barker P.M., Gillie D.J., Schechter M.S., Rubin B.K. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am J Respir Crit Care Med 2005, 171:868-871.
11. Wijnholds J., Evers R., van Leusden M.R., et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997, 11:1275-1279.
12. Siedlinski M., Boezen H.M., Boer J.M., Smit H.A., Postma D.S. ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet Genomics 2009, 19:675-684.
13. Wang Z., Wang B., Tang K., Lee E.J., Chong S.S., Lee C.G. A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 2005, 14:2075-2087.
14. Cozens A.L., Yezzi M.J., Chin L., Simon E.M., Finkbeiner W.E., Wagner J.A., et al. Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. Proc Natl Acad Sci U S A 1992, 89:5171-5175.
15. Zeitlin P.L., Lu L., Rhim J., Cutting G., Stetten G., Kieffer K.A., et al. A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection. Am J Respir Cell Mol Mol Biol 1991, 4:313-319.
16. Verkman A.S. Development and biological applications of chloride-sensitive fluorescent indicators. Am J Physiol 1990, 259:375-388.
17. Freeman J.V., Cole T.J., Chinn S., Jones P.R., White E.M., Preece M.A. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995, 73:17-24.
18. Knudson R., Lebowitz M., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
19. Döring G., Conway S.P., Heijerman H.G., Hodson M.E., Høiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767.
20. Kulich M., Rosenfeld M., Campbell J., Kronmal R., Gibson R.L., Goss C.H., et al. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005, 172:885-891.
21. Garred P., Pressler T., Madsen H.O., et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999, 104:431-437.
22. Dorfman R., Sandford A., Taylor C., et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008, 118:1040-1049.
23. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990, 116:714-719.
24. Konstan M.W., Morgan W.J., Butler S.M., et al. For the Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in FEV1 in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139.
25. Cystic Fibrosis Foundation Patient registry 1996 annual data report August 1997, Bethesda, Maryland.
26. Baumann U., Stocklossa C., Greiner W., von der Schulenburg J.M., von der Hardt H. Cost of the care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003, 2:84-90.
27. Slieker M.G., Sanders E.A., Rijkers G.T., Ruven H.J., van der Ent C.K. Disease modifying genes in cystic fibrosis. J Cyst Fibros 2005, 4:7-13.
28. Davies J., Griesenbach U., Alton E. Modifier genes in cystic fibrosis (CFTR state of the art series). Pediatr Pulmonol 2005, 39:383-391.
29. Boyle M.P. Strategies for identifying modifier genes in cystic fibrosis. Proc Am Thorac Soc 2007, 4:52-57.
30. Schultz M.J., Wijnholds J., Peppelenbosch M.P., et al. Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia. J Immunol 2001, 166:4059-4064.
31. van der Deen M., Timmens W., Timmer-Boscha H., et al. Reduced inflammtory response in cigarette smoke exposed MrpI/MdrIa/MdrIb deficiënt mice. Respir Res 2007, 8:49.